Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial.
暂无分享,去创建一个
A. Teoh | E. Ng | P. Chiu | W. Yeung | S. Y. Liu | S. Wong | S. K. Wong | A. Teoh | P.W.Y. Chiu | W.K. Yeung | S.Y.W. Liu | S. K. H. Wong | E. K. W. Ng
[1] Yi-Jen Chen,et al. Racial and ethnic disparities in outcomes with radiation therapy for rectal adenocarcinoma , 2012, International Journal of Colorectal Disease.
[2] C. Yen,et al. Tumor length assessed by miniprobe endosonography can predict the survival of the advanced esophageal squamous cell carcinoma with stricture receiving concurrent chemoradiation. , 2011, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[3] T. Shibata,et al. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. , 2011, Neoplasia.
[4] V. Gebski,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. , 2011, The Lancet. Oncology.
[5] M. Kranzfelder,et al. Meta‐analysis of neoadjuvant treatment modalities and definitive non‐surgical therapy for oesophageal squamous cell cancer , 2011, The British journal of surgery.
[6] A. Teoh,et al. Functional Performance and Quality of Life in Patients With Squamous Esophageal Carcinoma Receiving Surgery or Chemoradiation: Results From a Randomized Trial , 2011, Annals of surgery.
[7] T. Ruhstaller,et al. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). , 2010, Gastrointestinal endoscopy.
[8] Eugene H. Blackstone,et al. 7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction , 2010, Annals of Surgical Oncology.
[9] Nilay Shah,et al. Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer , 2010, Annals of Surgical Oncology.
[10] A. Hölscher,et al. [18F]-Fluorodeoxyglucose-Positron Emission Tomography for the Assessment of Histopathologic Response and Prognosis After Completion of Neoadjuvant Chemoradiation in Esophageal Cancer , 2009, Annals of surgery.
[11] Chun Meng Song,et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. , 2009, European Journal of Cancer.
[12] S. Baldus,et al. Response Evaluation by Endoscopy, Rebiopsy, and Endoscopic Ultrasound Does Not Accurately Predict Histopathologic Regression After Neoadjuvant Chemoradiation for Esophageal Cancer , 2008, Annals of surgery.
[13] Kenneth J. Chang,et al. Minimally Invasive Esophagectomy: Lessons Learned From 104 Operations , 2008, Annals of surgery.
[14] T. Conroy,et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Val Gebski,et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.
[16] V. Gebski,et al. AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP. SURVIVAL BENEFI TS FROM NEOADJUVANT CHEMORADIOTHERAPY OR CHEMOTHERAPY IN OESOPHAGEAL CARCINOMA: A META-ANALYSIS , 2007 .
[17] K. Geisinger,et al. Predictive Value of 18-Fluoro-Deoxy-Glucose-Positron Emission Tomography (18F-FDG-PET) in the Identification of Responders to Chemoradiation Therapy for the Treatment of Locally Advanced Esophageal Cancer , 2006, Annals of surgery.
[18] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[19] S. Leung,et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: Early results from the Chinese University Research Group for Esophageal Cancer (CURE) , 2005, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.
[20] Nils Lehmann,et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. D. De Leyn,et al. Three-Field Lymphadenectomy for Carcinoma of the Esophagus and Gastroesophageal Junction in 174 R0 Resections: Impact on Staging, Disease-Free Survival, and Outcome: A Plea for Adaptation of TNM Classification in Upper-Half Esophageal Carcinoma , 2004, Annals of surgery.
[22] R. Munden,et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. , 2004, The Annals of thoracic surgery.
[23] D. Stocken,et al. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Hainsworth,et al. Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5‐FU and Radiation Therapy in Locoregional Esophageal Cancer: Final Results of a Minnie Pearl Cancer Research Network Phase II Trial , 2003, Cancer journal.
[25] R. Ginsberg,et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Peters,et al. Curative Resection for Esophageal Adenocarcinoma: Analysis Of 100 En Bloc Esophagectomies , 2001, Annals of surgery.
[27] M. Feith,et al. Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World , 2001, Annals of surgery.
[28] S. Law,et al. Two-field dissection is enough for esophageal cancer. , 2001, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[29] J. Petiot,et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.
[30] K. Isono,et al. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. , 1991, Oncology.